Baumgartner H, Falk V, Bax JJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep 21;38(36):2739-2791. doi: 10.1093/eurheartj/ehx391. PubMed PMID: 28886619.
Nishimura RA, Otto CM, Bonow RO, et al; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 10;129(23):e521-643. doi: 10.1161/CIR.0000000000000031. Epub 2014 Mar 3. Erratum in: Circulation. 2014 Sep 23;130(13):e120. Dosage error in article text. Circulation. 2014 Jun 10;129(23):e651. PubMed PMID: 24589853.
Definition, Etiology, Clinical FeaturesTop
Mixed mitral valve disease refers to coexisting mitral stenosis (MS) and mitral regurgitation (MR).
Etiology: Rheumatic disease, less frequently degenerative or endocarditic lesions.
Clinical features are similar to that of MS and MR, and depend on which of these hemodynamic lesions is dominant (see Mitral Stenosis; see Mitral Regurgitation). Most frequently the systolic murmur typical of MR is prominent and may mask the soft rumble typical of MS. The first heart sound may be increased in intensity.
In patients with hemodynamically significant combined MS and MR, chest radiographs reveal enlargement of the left atrium and ventricle (also the right ventricle if the valve disease is severe and chronic) and features of pulmonary congestion, less frequently pulmonary hypertension. In patients with dominant MS the size of LV may be normal.
1. Pharmacologic treatment of heart failure.
2. Antithrombotic treatment in patients with atrial fibrillation.
4. Invasive treatment: Patients with coexisting moderate or severe MR are ineligible for percutaneous valvuloplasty; usually, treatment involves mitral valve replacement.